AHK-Cu Limited Evidence

What It Is

AHK-Cu is a synthetic copper-binding tripeptide composed of L-alanine, L-histidine, and L-lysine chelated to a divalent copper ion (Cu²⁺). Under International Nomenclature of Cosmetic Ingredients it is listed as Copper Tripeptide-3, distinguishing it from Copper Tripeptide-1 (GHK-Cu, the natural plasma tripeptide discovered by Loren Pickart in 1973). The peptide backbone — alanyl-histidyl-lysine — acts as a copper carrier, with histidine providing the primary nitrogen-donor coordination sphere around the Cu²⁺ ion and the alpha-amino and carboxyl termini contributing auxiliary copper-binding. Molecular weight of the peptide component is approximately 354 Da; the assembled AHK-Cu complex has an approximate molecular formula of C₁₅H₂₄CuN₆O₄.

Structurally, AHK-Cu differs from GHK-Cu by a single amino-acid substitution at position 1: alanine's methyl side-chain replaces glycine's single hydrogen. That one methyl group — an addition of CH₂ to the sidechain — changes the steric profile of the tripeptide without altering the copper-binding histidine or the lysine basic-charge anchor. The change is small in atomic terms but meaningful in cellular behavior: published work suggests AHK-Cu has a different activity profile than GHK-Cu in dermal-papilla-cell and hair-follicle systems, even though both peptides chelate copper similarly and both drive broadly overlapping fibroblast responses (collagen synthesis stimulation, VEGF upregulation, TGF-β1 modulation).

AHK-Cu is not a naturally occurring human peptide. Unlike GHK-Cu — which is endogenous to human plasma, saliva, and urine at nanogram-per-milliliter concentrations that decline with age — AHK-Cu is a purely synthetic cosmetic active. It was engineered specifically as a scalp/hair-follicle-targeting analog to capture the copper-peptide mechanism while positioning clearly outside the anti-aging / wound-healing market that GHK-Cu dominates. Commercial availability is essentially entirely in the cosmetic channel: cosmetic-grade powders (typically >95% HPLC purity, light-blue color from the Cu²⁺ charge-transfer band at ~530–620 nm) and pre-formulated liposomal hair serums from specialty peptide suppliers. It is not an approved pharmaceutical in any jurisdiction; it is a cosmetic ingredient used in leave-on hair-growth topical products.

The published research base on AHK-Cu specifically is unusually thin for a compound that has been commercially available for nearly two decades. A single peer-reviewed study — Pyo et al., Archives of Pharmacal Research, 2007 (PMID 17703734) — provides the foundational mechanistic data on AHK-Cu in dermal papilla cells and ex vivo human hair follicles. Most subsequent AHK-Cu mentions in the literature are citations to that paper, derivative manufacturer-sponsored in-vitro assays on dermal fibroblast cultures, cosmetic-industry white papers, or comparator notes in GHK-Cu review articles. The vast majority of the supporting biology is drawn from the much larger GHK-Cu, VEGF-in-hair-follicle, and dermal-papilla-cell literature — extrapolated to AHK-Cu by structural analogy and shared copper-peptide mechanism.

Mechanism of Action

AHK-Cu's claimed biological activity is built around two overlapping mechanisms: (1) bioavailable copper delivery to scalp dermal cells, and (2) a copper-peptide-specific signaling profile that favorably modulates hair-follicle dermal papilla biology. The proximal mechanism work is dominated by a single 2007 in-vitro/ex-vivo study; the broader framework is extrapolated from the much larger copper-peptide and VEGF-in-hair-follicle literatures.

• Copper delivery via tripeptide chelate — The Ala-His-Lys backbone acts as a bioavailable copper carrier. Histidine's imidazole nitrogen plus the peptide's amino and amide donors form a square-planar coordination sphere around the Cu²⁺ ion, stabilizing it against displacement by serum albumin and delivering intact copper to cell-surface receptors and copper-transport proteins. Copper is a required cofactor for lysyl oxidase (collagen/elastin cross-linking), tyrosinase, dopamine-β-hydroxylase, superoxide dismutase, and cytochrome c oxidase — all of which contribute to scalp tissue homeostasis.
• VEGF upregulation in dermal fibroblasts and dermal papilla cells — The anchoring in-vitro finding is that AHK-Cu at 10⁻¹² to 10⁻⁹ M concentrations stimulates VEGF production from cultured human dermal fibroblasts and dermal papilla cells (Pyo et al., 2007, PMID 17703734). VEGF is the dominant angiogenic driver of perifollicular vascularization. In transgenic VEGF-overexpression hair-follicle models, follicle size and hair shaft diameter increase measurably (Yano, Brown & Detmar, J Clin Invest, 2001, PMID 11181640); systemic anti-VEGF antibodies suppress follicle vascularization and shaft growth. VEGF-mediated angiogenesis is one of the best-established lever points in hair-follicle biology, and minoxidil's partial mechanism is VEGF upregulation in dermal papilla cells (Lachgar et al., Br J Dermatol, 1998, PMID 9580790).
• Dermal papilla cell proliferation — AHK-Cu (10⁻¹² – 10⁻⁹ M) increased the proliferation rate of cultured human dermal papilla cells. DPCs are the specialized mesenchymal fibroblasts at the base of each follicle that regulate entry into anagen, maintenance of anagen duration, and hair shaft size. Increased DPC number and responsiveness is mechanistically upstream of anagen elongation.
• Ex vivo hair follicle elongation — In whole human scalp hair follicles cultured ex vivo, AHK-Cu stimulated elongation of the hair shaft over 5–9 days of culture at the same low picomolar-to-nanomolar concentration range (Pyo et al., 2007). Ex vivo follicle culture is a standard pre-clinical model for hair-growth-promoting compound screening, though its translation to in-vivo scalp outcomes is imperfect.
• Anti-apoptotic signaling in DPCs — Bcl-2/Bax and caspase-3 — Annexin-V / PI flow cytometry in the Pyo 2007 work suggested a trend toward reduced apoptosis in 10⁻⁹ M AHK-Cu-treated DPCs (though the effect did not reach statistical significance). The Bcl-2-to-Bax ratio was elevated, and cleaved caspase-3 and cleaved PARP — downstream executioner-apoptosis markers — were reduced. This anti-apoptotic signal is mechanistically relevant because androgenetic alopecia involves progressive dermal-papilla-cell apoptosis and follicle miniaturization.
• TGF-β1 suppression in dermal fibroblasts — AHK-Cu decreases TGF-β1 secretion from cultured dermal fibroblasts. TGF-β1 is a pro-fibrotic and pro-catagen cytokine; it drives follicle regression and is implicated in DHT-mediated follicle miniaturization. Reduced TGF-β1 output is consistent with a pro-anagen, anti-catagen signaling profile.
• VEGFR2 / PI3K / Akt / ERK downstream — VEGF-mediated proliferation of human dermal papilla cells signals primarily through VEGFR2, with downstream PI3K/Akt and MEK/ERK activation (Li et al., 2012, PMID 22659165). AHK-Cu's VEGF upregulation is expected to engage this downstream axis indirectly through locally increased VEGF concentrations, rather than through direct AHK-Cu–receptor binding.
• Copper-peptide cross-talk with GHK-Cu biology — AHK-Cu and GHK-Cu share a copper-binding His-Lys C-terminal motif. GHK-Cu is the canonical copper-peptide active — extensively characterized across wound healing, collagen synthesis, elastin synthesis, decorin, glycosaminoglycan deposition, anti-inflammatory signaling, anti-oxidant gene upregulation, and hair-follicle stimulation (Maquart et al., 1988, PMID 3169264; Pickart et al., Biomed Res Int 2015, PMID 26236730; Pickart & Margolina, Int J Mol Sci 2018, PMID 29986520). The AHK substitution is positioned as trading some of GHK-Cu's broader skin-regenerative profile for greater selectivity toward dermal papilla / follicle biology — a commercially-driven positioning rather than a rigorously mapped mechanistic bifurcation.
• Keratinocyte involvement — Follicular keratinocytes of the outer root sheath are the dominant site of VEGF mRNA expression during mid-anagen (Yano et al., 2001); dermal papilla cells are also a source (Kozlowska et al., 1998, PMID 9879835). AHK-Cu's stimulation of VEGF in the dermal compartment likely complements, rather than replaces, keratinocyte-derived VEGF during the anagen phase.
• Anti-oxidant / copper-buffering role — Copper peptides reduce copper-driven Fenton-reaction oxidative damage by providing a chelated, safely-delivered form of copper, compared with free ionic Cu²⁺ which generates hydroxyl radicals. The antioxidant gene-expression modulation documented for GHK-Cu (Pickart, Vasquez-Soltero & Margolina 2018 gene-expression review, PMID 29986520) is likely partly shared by AHK-Cu, though not directly demonstrated in peer-reviewed AHK-Cu studies.

What the Research Shows

AHK-Cu's direct peer-reviewed research base is dominated by a single foundational in-vitro / ex-vivo paper. Most downstream evidence is inferred from the much larger copper-peptide, VEGF, and dermal-papilla-cell literatures. This is the compound's single most important scientific limitation.

• Pyo et al. 2007 (PMID 17703734) — foundational in-vitro / ex-vivo study — Published in Archives of Pharmacal Research by Pyo, Yoo, Won, Lee, Kang, Eun, Cho, and Kim of Seoul National University College of Medicine. Tested L-alanyl-L-histidyl-L-lysine-Cu²⁺ (AHK-Cu) at concentrations 10⁻¹² to 10⁻⁹ M in cultured human dermal papilla cells (DPCs) and human scalp hair follicles in organ culture. Key findings: AHK-Cu stimulated follicle elongation ex vivo across the full concentration range; AHK-Cu stimulated DPC proliferation at the same concentrations; AHK-Cu reduced Annexin-V–positive apoptotic DPC fraction (trend, not statistically significant); Bcl-2/Bax ratio increased; cleaved caspase-3 and cleaved PARP decreased under 10⁻⁹ M AHK-Cu treatment; dermal fibroblast VEGF secretion increased, TGF-β1 secretion decreased. This is the canonical AHK-Cu reference.
• Copper-peptide + VEGF in follicle angiogenesis — Yano, Brown & Detmar 2001 (PMID 11181640) — Journal of Clinical Investigation. Landmark study demonstrating that VEGF is a major mediator of hair follicle growth and cycling. Transgenic VEGF overexpression in outer-root-sheath keratinocytes increased perifollicular vascularization, accelerated hair regrowth after depilation, and increased hair follicle and shaft size. Systemic anti-VEGF antibody treatment reduced follicle vascularization and shaft size. Establishes the mechanistic target AHK-Cu's VEGF-upregulation claim addresses.
• Minoxidil VEGF upregulation in DPCs — Lachgar et al. 1998 (PMID 9580790) — British Journal of Dermatology. Minoxidil — the FDA-approved topical hair-growth drug — upregulates VEGF mRNA expression in cultured human hair dermal papilla cells. Establishes the precedent that DPC VEGF stimulation is a clinically validated hair-growth mechanism and positions AHK-Cu within the same pharmacological family conceptually (even though AHK-Cu is a copper peptide and minoxidil is a potassium-channel opener with different upstream biology).
• VEGF autocrine loop in DPCs — Lachgar et al. 1996 (PMID 8592070) — Identified VEGF as an autocrine growth factor for hair dermal papilla cells and demonstrated that DPC proliferation responds to VEGF in a dose-dependent manner. The autocrine loop provides a mechanistic substrate for AHK-Cu's stimulatory effect on DPC proliferation.
• VEGF / VEGFR2 in DPCs — Li et al. 2012 (PMID 22659165) — Demonstrated VEGFR2 expression on human hair follicle dermal papilla cells and showed that VEGF induces DPC proliferation through VEGFR2-mediated ERK activation. Connects AHK-Cu's upstream VEGF upregulation to a defined downstream signaling pathway.
• Foundational GHK-Cu collagen synthesis — Maquart et al. 1988 (PMID 3169264) — FEBS Letters. First demonstration that the tripeptide-copper complex GHK-Cu stimulates collagen synthesis in fibroblast cultures at concentrations 10⁻¹² to 10⁻⁹ M — the same active-concentration range later documented for AHK-Cu on dermal papilla cells. Establishes the copper-peptide class pharmacology at pico-to-nanomolar active concentrations.
• GHK-Cu gene-expression review — Pickart & Margolina 2018 (PMID 29986520) — International Journal of Molecular Sciences. Comprehensive review of GHK-Cu biology using Connectivity-Map gene-expression data. Documents GHK-Cu's effects on anti-inflammatory, anti-oxidant, collagen-synthesis, and DNA-repair gene sets. The indirect scaffold for many AHK-Cu mechanistic claims.
• GHK-Cu multi-pathway review — Pickart, Vasquez-Soltero & Margolina 2015 (PMID 26236730) — BioMed Research International. Broader Pickart review of copper-peptide pathways in skin regeneration. Backgrounds the copper-peptide mechanism framework used throughout the AHK-Cu literature.
• VEGF expression across hair-follicle compartments — Kozlowska et al. 1998 (PMID 9879835) — Compared VEGF mRNA expression across dermal papilla cells, fibrous-sheath fibroblasts, dermal fibroblasts, and follicular and interfollicular keratinocytes. Dermal papilla cells and follicular keratinocytes were the dominant VEGF-expressing compartments. Anchors AHK-Cu's dermal-papilla-centered positioning.
• Skin-regenerative and anti-cancer actions of copper peptides — Pickart & Margolina 2018 — Cosmetics 5(2):29. Broad-spectrum review of copper-peptide therapeutics. Places AHK-Cu within the wider copper-peptide cosmetic and dermatological-science context.
• Clinical hair-growth research is small and open-label — Published AHK-Cu human studies are typically small, open-label, vehicle-controlled cosmetic panels of 20–60 subjects testing leave-on hair serums containing 0.1–0.5% AHK-Cu, often in combination with other actives (GHK-Cu, biotinyl-GHK, caffeine, redensyl, minoxidil). Most are unpublished manufacturer reports or posters at cosmetic-science conferences. No placebo-controlled double-blind RCT of AHK-Cu monotherapy has been published.

Human Data

Unlike GHK-Cu — which has open-label cosmetic-panel data, a couple of small controlled hair studies, and a long wound-healing clinical footprint — AHK-Cu's human evidence base is minimal. The following is a candid inventory of what exists:

• No published placebo-controlled double-blind RCT of AHK-Cu monotherapy. Searches of PubMed, Google Scholar, ClinicalTrials.gov, and the Cochrane Central Register do not identify a placebo-controlled double-blind randomized trial of AHK-Cu as a single active in human androgenetic alopecia or general hair-loss populations. This is the dominant feature of the human-data landscape and must be held in mind when evaluating product claims.
• Open-label cosmetic hair-serum panels — Manufacturer-sponsored consumer panels typically evaluate leave-on serums containing 0.1–0.5% AHK-Cu in combination with other actives (GHK-Cu, biotinyl-tripeptide-1, caffeine, niacinamide, redensyl, capixyl, procapil). Endpoints are usually subjective self-report (hair feels thicker, shedding reduced), phototrichogram hair-count measurements on small scalp patches over 3–6 months, or before/after photography. Reported improvements are modest and confounded by combination-product design, placebo effects, and seasonal hair-cycle variation. These panels do not constitute rigorous clinical evidence.
• Combination-product context — minoxidil adjunct — AHK-Cu appears in multiple cosmetic serums positioned as a topical adjunct to minoxidil or finasteride therapy. The rationale is mechanistic complementarity: AHK-Cu's VEGF stimulation and anti-apoptotic DPC signaling theoretically supports, rather than competes with, minoxidil's potassium-channel-opener and VEGF-upregulating mechanism. No peer-reviewed head-to-head or adjunctive-therapy trial of AHK-Cu + minoxidil has been published to our knowledge.
• Cosmetic safety history — AHK-Cu has been in commercial cosmetic use for nearly two decades without safety signals generating regulatory action. Cosmetic-ingredient reviews classify it as low-irritation at typical leave-on concentrations (0.05–0.5%) in properly formulated vehicles. This is a weak positive — absence of evidence of harm rather than presence of evidence of efficacy.
• Hair-transplant post-op protocols — Some hair-transplant surgeons in the United States, Turkey, Korea, and India incorporate topical copper peptides (GHK-Cu and/or AHK-Cu) into post-operative scalp serums on the rationale that copper-peptide anti-inflammatory and angiogenic signaling may support graft take. Evidence is anecdotal and clinic-specific; no controlled post-transplant trial isolating AHK-Cu effect has been published.
• Scalp-microneedling + AHK-Cu protocols — Dermatology clinics increasingly pair topical AHK-Cu with scalp microneedling (0.5–1.5 mm depth, weekly to biweekly) on the mechanistic rationale that microneedling increases dermal penetration and activates wound-signaling that copper-peptide signaling overlaps. Published microneedling-plus-minoxidil trials (Dhurat et al., 2013) support the microneedling concept; AHK-Cu's role in such stacks is extrapolated, not directly tested.

The honest summary is that AHK-Cu's human evidence base is thin. Cosmetic formulation history is substantial; peer-reviewed human efficacy data is minimal. The compound's clinical standing rests almost entirely on the mechanistic framework documented in vitro and ex vivo in 2007, scaffolded by the much larger GHK-Cu and VEGF-in-follicle literatures. This is a reasonable position for a cosmetic adjunct; it is not a position that supports treating AHK-Cu as a standalone alopecia therapy.

Dosing from the Literature

AHK-Cu is a topical cosmetic ingredient. "Dosing" refers to formulation concentration in leave-on scalp/hair products and typical application frequency, not to systemic administration. There is no published clinical dose-response study for AHK-Cu in humans; the concentration range below reflects cosmetic-industry formulation practice and in-vitro active concentrations (10⁻¹² – 10⁻⁹ M) used in the Pyo 2007 work.

Cosmetic formulations vary widely in vehicle design, which dramatically affects how much intact AHK-Cu reaches the dermal papilla layer. Hydroalcoholic, liposomal, ionic-liquid-microemulsion, and polymer-thickened vehicles all have different penetration profiles; simple aqueous vehicles typically deliver less. Product-label concentration is not a reliable proxy for delivered dose.

Reconstitution & Storage

AHK-Cu is typically supplied either as a cosmetic-grade lyophilized powder (for formulators) or pre-dissolved in a stabilized cosmetic vehicle (for end-consumer serums). Both forms are chemically sensitive. The copper-chelate bond is the most fragile element — photo-degradation, pH drift, and oxidative / reductive partners will all destabilize the complex and reduce biological activity. Real-world product quality varies widely for this reason.

• Stability checkpoint — visible color — The intact Cu²⁺-peptide chelate is blue. Product that has drifted to green, gray, or colorless has lost significant copper coordination and will have reduced biological activity.
• pH control is the dominant stability variable — Copper-peptide chelates are most stable in the slightly acidic-to-neutral range (pH 5.5–7.0). Vehicles that drift below pH 4 (L-ascorbic acid, glycolic acid) or above pH 8 strip the copper. Sequence pH-incompatible actives so they do not contact AHK-Cu in the same application layer.
• Do not refrigerate finished serums unless the label directs — Many commercial AHK-Cu serums use room-temperature-stable vehicles; refrigeration can precipitate the peptide or crack the vehicle. Follow product-label storage.
• Single-use layering — For home-formulated or prosumer stacks, apply AHK-Cu first to clean dry scalp, allow 2–3 minutes absorption, then layer other actives. Avoid immediate layering with vitamin C, AHAs/BHAs, benzoyl peroxide, or high-strength retinoids.
• Cross-check COA / HPLC purity — Peptide supplier quality varies. Insist on a recent Certificate of Analysis showing >95% HPLC purity, residual-solvent profile, and copper content. Low-grade AHK-Cu may contain excess free Cu²⁺ (which is pro-oxidant at skin pH) or truncated peptide fragments.

→ Use the Kalios Dosing Calculator for topical concentration conversions

Side Effects & Risks

AHK-Cu has been in cosmetic use for nearly two decades without major regulatory safety actions. Risk profile is that of a topical cosmetic copper peptide rather than a systemic therapeutic; most issues are local and formulation-related.

• Scalp irritation — Mild-to-moderate transient stinging, redness, or mild burning on freshly washed or microneedled scalp. More common with high-concentration formulations (0.3–0.5%), hydroalcoholic vehicles, or heavily fragranced products. Typically self-limiting; discontinuing the product resolves the reaction within a few days.
• Contact dermatitis / copper sensitization — A small subset of users develop a true allergic contact dermatitis to copper peptides. Characterized by localized erythema, scaling, and itch at the application site, sometimes with spreading to the forehead or nape. Patch testing by a dermatologist is diagnostic. Prior nickel, cobalt, or chromate allergy may predict copper sensitization in some individuals. Discontinue and consult a dermatologist.
• Scalp dryness / flaking — Some AHK-Cu serums use hydroalcoholic vehicles that dry scalp surfaces. Typically corrected by switching to a liposomal or glycerin-based vehicle or by reducing frequency of application.
• Blue-green staining — Concentrated AHK-Cu serums can produce faint blue-green color on towels, pillowcases, or light-colored hair. Cosmetic, not medically concerning.
• Hair-shaft color interaction — Anecdotal reports of temporary greenish cast on bleached or platinum hair when used at high concentrations for extended periods. The Cu²⁺ can deposit on porous hair-shaft cuticles. Not a medical risk; reversed by chelating shampoos.
• Systemic copper exposure — At cosmetic concentrations (0.05–0.5%) on intact scalp skin, systemic copper absorption is negligible relative to dietary copper intake. On broken scalp, freshly microneedled skin, or open grafts, percutaneous absorption is higher — avoid high-concentration AHK-Cu on freshly needled scalp without clinician guidance.
• Not for Wilson disease / copper overload — Patients with Wilson disease (autosomal recessive copper accumulation) should avoid copper-peptide topicals; even small additional copper exposure can be clinically relevant. Consult a hepatologist or internist if unsure.
• Pregnancy and breastfeeding — No human reproductive-safety data. Standard cosmetic-science caution applies: avoid where possible, or consult an OB/GYN before continued use during pregnancy or lactation.
• Pediatric use — No pediatric data. Not recommended for children and adolescents outside dermatologist supervision.
• Drug interactions — AHK-Cu is topical and systemic exposure is negligible, so pharmacological drug interactions are not expected. Local vehicle-level interactions with other scalp actives (minoxidil, topical finasteride, retinoids, AHAs/BHAs) can occur — sequence applications and consult a clinician.
• No WADA relevance — AHK-Cu is a topical cosmetic copper peptide; it is not named on the WADA Prohibited List and is not a plausible candidate for anti-doping concern at cosmetic-use concentrations. Systemic peptide-analog concerns apply to injectable peptides, not topical copper-tripeptide actives.
• Purity / adulteration risk — "AHK-Cu" sold through low-reputation suppliers may be under-dosed, oxidized, or adulterated with free copper salts. Demand HPLC COA. Prefer suppliers and finished brands with independent third-party testing.

Bloodwork & Monitoring

AHK-Cu is a topical cosmetic; routine bloodwork is not indicated for cosmetic-use concentrations on intact scalp skin. Monitoring recommendations below are conservative and apply principally to users with underlying copper-metabolism disease, extensive scalp disruption (post-transplant, post-microneedling), or combination-therapy contexts.

• Routine labs — not needed for standard cosmetic use — At 0.05–0.5% AHK-Cu applied to intact scalp, systemic exposure is orders of magnitude below dietary copper intake and does not require monitoring.
• Consider serum ceruloplasmin & serum copper — If there is any suspicion of Wilson disease, chronic liver disease, or a history of copper accumulation, baseline serum ceruloplasmin and serum copper are reasonable before beginning extended-use copper-peptide topical regimens.
• Liver function (CMP) — For users with chronic liver disease, alcohol-use history, or hepatitis, a baseline CMP is reasonable given the liver's central role in copper homeostasis.
• Scalp biopsy / clinical dermatoscopy — In patients using AHK-Cu as a hair-loss adjunct without prior diagnosis, clinical trichoscopy or scalp biopsy by a dermatologist is the first-line diagnostic step to distinguish androgenetic alopecia from alopecia areata, telogen effluvium, lichen planopilaris, or frontal fibrosing alopecia. AHK-Cu is not a treatment for cicatricial (scarring) alopecias, and using it without a diagnosis can delay appropriate care.
• Phototrichogram / standardized hair-count photography — For users tracking cosmetic effect: baseline and 12–24-week standardized scalp photography (consistent lighting, distance, parting) is the simplest non-clinical way to assess change. Expectations should be modest.
• Patch testing — For users with nickel, cobalt, or chromate contact allergy history, a dermatologist-administered copper patch test before starting chronic AHK-Cu exposure is reasonable.
• Pregnancy test / OB guidance — Women planning pregnancy should consult their OB/GYN before continuing any topical hair-loss regimen.
• No WADA-relevant testing — AHK-Cu is topical and cosmetic; it is not a doping concern and no sport-specific testing is warranted.

Commonly Stacked With

AHK-Cu is almost always used as part of a multi-active scalp/hair stack rather than as monotherapy. The most common partner actives reflect complementary mechanisms: copper-peptide biology (GHK-Cu), potassium-channel-opener vasodilation (minoxidil), 5-alpha-reductase inhibition (finasteride, dutasteride), growth-factor mimicry (biotinyl-GHK, Cu-based biotinylated peptides), and procedural adjuncts (microneedling, platelet-rich plasma). The following are the most-published combinations:

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

Copper-tripeptide family and adjacent follicle-signaling peptides:

Next Steps

Key References

1. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. doi:10.1007/BF02978833. PMID: 17703734. (The foundational AHK-Cu in-vitro / ex-vivo paper — dermal papilla cell proliferation, ex vivo follicle elongation, anti-apoptotic Bcl-2/Bax and caspase-3/PARP effects, VEGF and TGF-β1 modulation at 10⁻¹² – 10⁻⁹ M.)
2. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107(4):409-417. doi:10.1172/JCI11317. PMID: 11181640. (Transgenic VEGF overexpression increases perifollicular vascularization, accelerates hair regrowth, and increases follicle / shaft size; anti-VEGF antibody reduces follicle size — establishes VEGF as a major hair-growth mediator.)
3. Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138(3):407-411. doi:10.1046/j.1365-2133.1998.02115.x. PMID: 9580790. (Clinically validated positive-control mechanism — DPC VEGF upregulation — that AHK-Cu's mechanism claim parallels.)
4. Lachgar S, Charveron M, Gall Y, Bonafe JL. Vascular endothelial growth factor is an autocrine growth factor for hair dermal papilla cells. J Invest Dermatol. 1996;106(1):17-23. PMID: 8592070. (Establishes VEGF-DPC autocrine loop — mechanistic substrate for AHK-Cu's DPC proliferation effect.)
5. Li W, Man XY, Li CM, Chen JQ, Zhou J, Cai SQ, Lu ZF, Zheng M. VEGF induces proliferation of human hair follicle dermal papilla cells through VEGFR-2-mediated activation of ERK. Exp Cell Res. 2012;318(14):1633-1640. doi:10.1016/j.yexcr.2012.05.003. PMID: 22659165. (Downstream VEGFR2-ERK pathway connecting AHK-Cu's VEGF upregulation to DPC proliferation.)
6. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. doi:10.1016/0014-5793(88)80509-x. PMID: 3169264. (Foundational copper-peptide class pharmacology at pico-to-nanomolar concentrations — same range AHK-Cu is active in.)
7. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520. (Comprehensive review of copper-peptide gene-expression effects — scaffold for AHK-Cu mechanism extrapolation.)
8. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26236730. (Multi-pathway copper-peptide mechanism review — foundational context for AHK-Cu positioning.)
9. Kozlowska U, Blume-Peytavi U, Kodelja V, Sommer C, Goerdt S, Majewski S, Jablonska S, Orfanos CE. Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle. Arch Dermatol Res. 1998;290(12):661-668. doi:10.1007/s004030050370. PMID: 9879835. (Compartment-resolved VEGF expression across DPCs, fibrous sheath, dermal fibroblasts, and follicular keratinocytes — anchors AHK-Cu's dermal-papilla-centered claim.)
10. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. doi:10.1163/156856208784909435. PMID: 18644225. (Authoritative Pickart review of the copper-peptide tissue-remodeling framework.)
11. Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29. doi:10.3390/cosmetics5020029. (Broad copper-peptide review placing AHK-Cu within the wider class context.)
12. Siméon A, Wegrowski Y, Bontemps Y, Maquart FX. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000;115(6):962-968. doi:10.1046/j.1523-1747.2000.00166.x. PMID: 11121126. (Copper-peptide class effect on extracellular-matrix turnover in wound healing — background for AHK-Cu scalp-regenerative rationale.)
13. Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A Randomized Evaluator Blinded Study of Effect of Microneedling in Androgenetic Alopecia: A Pilot Study. Int J Trichology. 2013;5(1):6-11. doi:10.4103/0974-7753.114700. PMID: 23960389. (Microneedling + minoxidil RCT — the procedural-adjunct framework AHK-Cu stacks extend.)
14. Miller DM, DeSilva D, Pickart L, Aust SD. Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Adv Exp Med Biol. 1990;264:79-84. doi:10.1007/978-1-4684-5730-8_11. PMID: 2244554. (Copper-peptide anti-oxidant buffering mechanism — relevant to AHK-Cu's copper-safe-delivery claim.)
15. Matsuzaki T, Yoshizato K. Role of hair papilla cells on induction and regeneration processes of hair follicles. Wound Repair Regen. 1998;6(6):524-530. doi:10.1046/j.1524-475x.1998.60605.x. PMID: 9893172. (Dermal papilla cell biology as the master regulator of follicle induction and regeneration — the cellular target of AHK-Cu's published activity.)
16. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832. doi:10.1155/2012/324832. PMID: 22666519. (Copper-peptide aging-biology review — context for the copper-peptide family's broader systems-biology positioning.)
17. Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics. 2015;2(3):236-247. doi:10.3390/cosmetics2030236. (Copper-peptide anti-oxidant gene-expression framework — contextualizes AHK-Cu's scalp redox-environment claim.)
18. Simeon A, Monier F, Emonard H, Gillery P, Birembaut P, Hornebeck W, Maquart FX. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 1999;112(6):957-964. doi:10.1046/j.1523-1747.1999.00606.x. PMID: 10383745. (Copper-peptide MMP modulation — extracellular-matrix framework underpinning copper-peptide regenerative claims.)